---
layout: default
title: Fulvestrant
description: "Fulvestrant drug repurposing predictions from TxGNN. Evidence level L5 with 50 predicted indications."
parent: AI Predictions (L5)
nav_order: 258
evidence_level: L5
indication_count: 50
---

# Fulvestrant
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **50**
{: .fs-6 .fw-300 }

---

## Quick Overview

| Item | Value |
|------|-------|
| Drug Name | Fulvestrant |
| DrugBank ID | [DB00947](https://go.drugbank.com/drugs/DB00947) |
| Brand Names (EU) | Faslodex |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.91% |

---

## Approved Indication (EMA)

Faslodex is indicated  as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:  not previously treated with endocrine therapy, or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.   in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breas

---

## Predicted New Indications

TxGNN model predictions for potential drug repurposing:

| Rank | Indication | Score | Source |
|:----:|------------|------:|--------|
| 1 | HIV infectious disease | 99.91% | DL |
| 2 | multiple endocrine neoplasia | 99.85% | DL |
| 3 | simian immunodeficiency virus infection | 99.83% | DL |
| 4 | feline acquired immunodeficiency syndrome | 99.83% | DL |
| 5 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 99.82% | DL |
| 6 | rheumatoid arthritis | 99.58% | DL |
| 7 | acne (disease) | 99.37% | DL |
| 8 | brachydactyly-syndactyly syndrome | 99.29% | DL |
| 9 | hemoglobinopathy | 99.29% | DL |
| 10 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 99.16% | DL |
| 11 | psoriasis | 99.15% | DL |
| 12 | pyropoikilocytosis, hereditary | 99.07% | DL |
| 13 | beta-thalassemia with other manifestations | 99.04% | DL |
| 14 | partial deletion of the short arm of chromosome 16 | 99.02% | DL |
| 15 | oral candidiasis | 98.96% | DL |
| 16 | hemolytic anemia due to glucophosphate isomerase deficiency | 98.92% | DL |
| 17 | homozygous familial hypercholesterolemia | 98.83% | DL |
| 18 | pyruvate kinase deficiency of red cells | 98.75% | DL |
| 19 | obsolete familial combined hyperlipidemia | 98.73% | DL |
| 20 | commissural lip fistula | 98.72% | DL |

*Showing top 20 of 50 predictions.*

---

## About TxGNN Predictions

### Prediction Sources

| Source | Description |
|--------|-------------|
| **KG** | Knowledge Graph - Network topology-based associations |
| **DL** | Deep Learning - Neural network score prediction |

### Evidence Levels

| Level | Definition |
|:-----:|------------|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| **L5** | AI prediction only (current) |

---

## Clinical Validation Needed

<div style="background: #fff3cd; padding: 1rem; border-left: 4px solid #ffc107; border-radius: 4px; margin: 1rem 0;">
<strong>Research Use Only:</strong> These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
</div>

### Next Steps for Validation

1. **Literature Review**: Search PubMed for existing evidence
2. **Clinical Trial Search**: Check ClinicalTrials.gov for ongoing studies
3. **Mechanistic Analysis**: Evaluate biological plausibility
4. **Preclinical Studies**: Conduct in vitro/in vivo validation
5. **Clinical Trials**: Design and conduct human studies

---

## Data Access

- **FHIR API**: `/fhir/ClinicalUseDefinition/`
- **CSV Download**: [All Predictions](/downloads/)
- **GitHub**: [yao-care/EuTxGNN](https://github.com/yao-care/EuTxGNN)

---

## Citation

If using this data, please cite:

```bibtex
@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
```

---

<div style="background: #f8f9fa; padding: 1rem; border-radius: 4px; font-size: 0.9rem;">
<strong>Disclaimer:</strong> This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.
</div>
